The association of HLA-C alleles with multiple myeloma in Chinese patients

Xiaojing Wang1, Gang An2, Jiying Wang1, Yan Zhang1, Qinghua Li1, Hui wei3, Lugui Qiu2 and Kun Ru1*

Abstract

Background: The positive association of multiple myeloma (MM) risk with HLA-C loci C*07:02 g and C*02:02 g, and the negative association of that with C*05:01 g were statistically significant in Whites have recently been reported. However, no association between HLA-C alleles and MM risk was found in Asians/Pacific Islanders. Here we identified 316 Chinese patients with MM, and reported the results of our investigation of HLA-C in MM in Chinese population.

Methods: We identified 316 Chinese patients with MM diagnosed in our hospital, and typed for HLA-C by using Sanger sequence-based typing. The control was from laboratories of China Marrow Donor Program (CMDP), where HLA high resolution was provided in 564,856 volunteer adult donors.

Results: In contrast to the association of MM risk in Whites, we did not find the similar association in Chinese population. Nevertheless, four new associations between the MM risk were identified in Chinese patients. Our data demonstrated that Chinese patients with MM carry significantly increased frequencies of HLA-C*03:03 (FDR = 0.0269), HLA-C*07:63 (FDR = 0.0278) and HLA-C*08:22 (FDR = 0.0442) comparing with controls, while significantly decreased frequency of HLA-C*01:02 (FDR = 0.0414) comparing with controls.

Conclusion: Therefore, HLA-C region is a key risk locus for MM in Chinese population.

Keywords: Multiple myeloma, Human leukocyte antigen, Allele, Chinese population
HLA-C high resolution typing
Genomic DNAs of patients’ peripheral blood were extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Patients were typed for HLA-C by using Sanger sequence-based typing (GenDx, Netherlands). The sequence products were separated on ABI 3730 Genetic Analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan), and analyzed with SBTengine analysis software (GenDx, Netherlands). Ambiguous allele combinations were solved by GSSP (Group Specific Sequencing Products) primers (GenDx, Netherlands).

In addition, public data were used as control from laboratories of China Marrow Donor Program (CMDP), where HLA high resolution was provided in 564,856 volunteer adult donors using DNA-based methods (Sanger sequence-based typing or sequence-specific oligonucleotide) [6].

Statistical analysis
Allele frequency (AF) is the frequency (proportion) of alleles in a population sample (n), so \( AF = \frac{\text{Alleles}}{2n} \).

By using Chi square and Fisher exact tests, comparisons between HLA-C alleles of MM patients and the controls were performed. SPSS 17.0 for Windows was used for analysis and \( P < 0.05 \) was considered to be statistically significant. Odds ratio (OR) and 95% confidence interval (CI) were determined. The \( P \)-values were adjusted for multiple testing using false discovery rate (FDR) with a 5% threshold [7].

Table 1 Allele frequencies of HLA-C alleles in patients with MM and in controls

| HLA-C | MM (n = 316) | Control (n = 564,856) | \( P \)-value | OR | 95% CI | FDR \( P \)-value |
|-------|-------------|---------------------|--------------|----|--------|-----------------|
| C*01:02 | 75 (11.8671%) | 179,483 (15.8875%) | 0.005706 | 0.713 | 0.560–0.907 | 0.0442 |
| C*01:03 | 4 (0.6329%) | 7098 (0.6283%) | 1.000000 | 1.007 | 0.377–2.693 | 1.033 |
| C*01:06 | 1 (0.1582%) | 959 (0.08489%) | 0.415580 | 1.865 | 0.262–13.276 | 0.6135 |
| C*02:02 | 5 (0.7911%) | 7796 (0.69009%) | 0.947008 | 1.148 | 0.476–2.768 | 1.0873 |
| C*03:02 | 25 (3.9557%) | 67,104 (5.93195%) | 0.034862 | 0.652 | 0.437–0.973 | 0.1544 |
| C*03:03 | 63 (9.9684%) | 78,335 (6.93407%) | 0.002686 | 1.486 | 1.145–1.928 | 0.0278 |
| C*03:04 | 54 (8.5443%) | 112,096 (9.92253%) | 0.246598 | 0.848 | 0.642–1.121 | 0.497 |
| C*04:01 | 35 (5.5380%) | 65,172 (5.7689%) | 0.803415 | 0.958 | 0.681–1.347 | 1.0377 |
| C*04:03 | 4 (0.6329%) | 11,488 (1.0169%) | 0.336047 | 0.620 | 0.232–1.657 | 0.5209 |
| C*04:82 | 2 (0.3165%) | 2771 (0.24528%) | 1.000000 | 1.291 | 0.322–5.176 | 1.000 |
| C*05:01 | 2 (0.3165%) | 9626 (0.85208%) | 0.142966 | 0.369 | 0.092–1.480 | 0.3409 |
| C*06:02 | 73 (11.5506%) | 100,031 (8.85456%) | 0.017080 | 1.344 | 1.053–1.716 | 0.1059 |
| C*07:01 | 7 (1.1076%) | 6394 (0.56598%) | 0.121410 | 1.968 | 0.934–4.146 | 0.3136 |
| C*07:02 | 78 (12.3418%) | 171,619 (15.19139%) | 0.046002 | 0.786 | 0.620–0.996 | 0.1585 |
| C*07:04 | 6 (0.9494%) | 9810 (0.86836%) | 0.826323 | 1.094 | 0.490–2.445 | 1.0246 |
| C*07:06 | 8 (1.2658%) | 9024 (0.79879%) | 0.187375 | 1.592 | 0.792–3.199 | 0.4149 |
| C*07:154 | 1 (0.1582%) | 154 (0.01363%) | 0.083042 | 11.624 | 1.625–83.175 | 0.2340 |
| C*07:63 | 2 (0.3165%) | 106 (0.00938%) | 0.001734 | 33.831 | 8.333–137.341 | 0.0269 |
| C*08:01 | 54 (8.5443%) | 96,496 (8.54165%) | 0.998093 | 1.000 | 0.757–1.322 | 1.0669 |
| C*08:02 | 5 (0.7911%) | 3406 (0.30149%) | 0.059990 | 2.637 | 1.093–6.362 | 0.1860 |
| C*08:03 | 8 (1.2658%) | 8754 (0.77489%) | 0.237089 | 1.642 | 0.817–3.298 | 0.4611 |
| C*08:22 | 13 (2.0570%) | 9836 (0.87056%) | 0.001336 | 2.391 | 1.380–4.143 | 0.0414 |
| C*12:02 | 29 (4.5886%) | 35,383 (3.13204%) | 0.035605 | 1.487 | 1.025–2.159 | 0.1380 |
| C*12:03 | 16 (2.5316%) | 21,799 (1.92961%) | 0.271411 | 1.320 | 0.803–2.169 | 0.4674 |
| C*14:02 | 23 (3.6392%) | 48,357 (4.28047%) | 0.425915 | 0.845 | 0.557–1.281 | 0.6002 |
| C*14:03 | 9 (1.4241%) | 11,482 (1.01637%) | 0.307052 | 1.407 | 0.728–2.717 | 0.5010 |
| C*15:02 | 21 (3.3282%) | 37,813 (3.43714%) | 0.972856 | 0.992 | 0.642–1.534 | 1.0711 |
| C*15:04 | 1 (0.1582%) | 432 (0.03824%) | 0.215112 | 4.143 | 0.581–29.522 | 0.4446 |
| C*15:05 | 3 (0.4747%) | 7914 (0.70053%) | 0.658438 | 1.275 | 0.217–2.102 | 0.8875 |
| C*16:02 | 2 (0.3165%) | 2292 (0.20288%) | 0.847597 | 1.562 | 0.389–6.261 | 1.0106 |
| C*17:01 | 3 (0.4747%) | 1154 (0.10215%) | 0.027885 | 4.664 | 1.498–14.522 | 0.1441 |

Italic values indicate FDR < 0.05

OR odds ratio, CI confidence interval, FDR false discovery rate
Results
The allele frequencies, i.e. gene frequencies, instead of phenotype frequencies were examined as recommended for HLA-disease association studies [8]. As listed in Table 1, there were 31 HLA-C alleles in 316 patients with MM. After Chi square and Fisher exact tests, we found nine alleles had significant P-values. The results indicated that the frequencies of C*01:02 (11.8671% vs. 15.8875%, OR = 0.786), C*03:02 (3.9557% vs. 5.93195%, OR = 0.652), C*07:02 (12.3418% vs. 15.19139%, OR = 0.786) were decreased, whereas the frequencies of C*03:03 (9.9684% vs. 6.93407%, OR = 1.486), C*06:02 (11.5506% vs. 8.85456%, OR = 1.344), C*07:63 (0.3165% vs. 0.00938%, OR = 33.831), C*08:22 (2.0570% vs. 0.87066%, OR = 2.391), C*12:02 (4.5886% vs. 3.13204%, OR = 1.487), C*17:01 (0.4747% vs. 0.10215%, OR = 4.664) were increased in Chinese patients with MM.

The P-values were adjusted for multiple testing using FDR. Further analysis among those nine alleles revealed that the adjusted P-values from C*01:02, C*03:03, C*07:63 and C*08:22 alleles were < 0.05 after adjustment for multiple comparisons. Therefore, our data demonstrated that Chinese patients with MM carry significantly increased frequencies of HLA-C*03:03 (FDR = 0.0269), HLA-C*07:63 (FDR = 0.0278) and HLA-C*08:22 (FDR = 0.0442) comparing with controls, while significantly decreased frequency of HLA-C*01:02 (FDR = 0.0414) comparing with controls.

Discussion
The HLA system, which is located on 6p21.3, is the most polymorphic of all human genetic systems. Some HLA alleles occur at a much higher frequency in those suffering from certain diseases than in the general population. In genome-wide association study (GWAS) demonstrate that the HLA region is a key risk locus for mature B cell malignancies [2, 9]. Europe PMC Funders Group conducted a GWAS study and identified a risk variant within HLA region for MM risk, but the associated single-nucleotide polymorphisms (SNPs) at 6p21.33 (rs2285803) was not directly characterized with classical HLA typing [10].

In our study we explored the association of HLA-C alleles with MM in Chinese patients. In contrast to the positive association of MM risk with C*07:02 g and C*02:02 g, as well as the negative association of that with C*05:01 g in Caucasian population, we failed to find the similar association in Chinese population. Nevertheless, some new associations between the MM risk and HLA-C alleles were identified in Chinese patients. It appears that the association of MM risk and HLA alleles varies depending on different ethnic groups [5].

Multiple comparisons correction refers to the need to correct a significance level for the number of hypothesis tests performed. One of the most widely used multiple testing criterions for controlling errors of false discoveries is False discovery rate (FDR). Therefore, our P-values were adjusted for multiple testing using FDR. Our results indicated that the positive association of MM risk with C*03:03, C*07:63 and C*08:22, as well as the negative association of that with C*01:02 in Chinese population. The frequency distribution of HLA alleles differs significantly among different human populations [11]. According to the Chinese common and well-documented (CWD) 2.2 catalogue, which was assembled by CMDP in February 2016, C*01:02, C*03:03, C*08:22 are common alleles (gene frequencies greater than 0.1% [12]), and C*07:63 is a well-documented allele (alleles observed in at least three independent unrelated individuals [12]) in Chinese population. However, based on the CWD 2.0.0 catalogue assembled from worldwide population in 2012 by American Society for Histocompatibility and Immunogenetics (ASHI), C*01:02, C*03:03, C*08:22 are common alleles, and C*08:22, C*07:63 are rare alleles in other ethnic populations [13]. This explains why the true association of C*08:22 and C*07:63 alleles with MM were not discovered among Whites and Blacks.

Besides MM, many previous studies showed that HLAs were associated with other haematological cancers. An association study found 6 protective or predisposing HLA-C alleles for chronic lymphocytic leukemia (CLL) in whites. Three alleles were protective (C*05:01, C*07:01, C*16:01) and 3 predisposing (C*03:04, C*12:03, C*16:02) [14]. A US population-based case–control study showed that HLA-B*08 was independently associated with non-Hodgkin lymphoma (NHL) risk in whites [15]. In Chinese population, our previous results indicated that as compared with the control, the frequency of HLA-DRB1*09 in ALL group significantly decreased (10.87% versus 16.08%, P = 0.014), while the frequency of HLA-B*18 in CML group was significantly higher (1.28% versus 0.20%, P = 0.039) [3]. We also found the frequency of HLA-DRB1*15 in childhood ALL was higher than those in control (22.62% versus 16.81%, P = 0.018) [4].

In summary, we discovered the positive association of MM risk with C*03:03, C*07:63 and C*08:22, as well as the negative association of that with C*01:02 in Chinese population. Therefore, HLA-C region is a key risk locus for MM in Chinese population.

Authors’ contributions
XJW, HW and KR contributed to the conception and design of this study. XJW performed the statistical and wrote the manuscript. JYW, YZ and QHL acquired, analyzed and interpreted the data. GA and LGQ provided clinical data for the samples used in this study. All authors read and approved the final manuscript.
Author details
1 Department of Pathology and Lab Medicine, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China. 2 Department of Lymphoma, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 3 Department of Leukemia, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated during this study are included in this published article.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study design was approved by the Ethics Committee of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, reference NI2017002-EC-1.

Funding
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81500134 & 81670159) and CAMS Innovation Fund for Medical Sciences (CIFMS 2016-I2M-3-004).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 May 2018 Accepted: 17 August 2018
Published online: 23 August 2018

References
1. Niens M, Jarrett RF, Hekkema B, Nolte IM, Diepstra A, Platteel M, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV + Hodgkin lymphoma. Blood. 2007;110:3310–5.
2. Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chilidi MC, et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood. 2013;122:1448–54.
3. Wang XJ, Zhang YZ, Sun HY, Li QH, Ru K. Associations of HLA gene with leukemia in 1186 cases. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;42:263–8.
4. Wang XJ, Ai XF, Sun HY, Wang F, Xu SC, Gui FM, et al. Relation of HLA-DRB1*15 with pathogenesis in 162 childhood cases of acute lymphoblastic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:1507–10.
5. Beksec M, Gragert L, Fingerson S, Maires M, Zhang M, Albrecht M, et al. HLA polymorphism and risk of multiple myeloma. Leukemia. 2016;30:2260–4.
6. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens. 2012;80:1–11.
7. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological). 1995;57:289–300.
8. Svejgaard A, Ryder UP. HLA and disease associations: detecting the strongest association. Tissue Antigens. 1994;43:18–27.
9. Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X, et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood. 2010;115:4820–3.
10. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45:1221–5.
11. Cao K, Hollenbach J, Shi X, Shi W, Chepek M, Fernandez-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009–30.
12. Cano P, Klitz W, Mack SJ, Maers M, Marsh SG, Noreen H, et al. Common and well-documented HLA alleles: report of the Ad-Hoc committee of the american society for histocompatibility and immunogenetics. Hum Immunol. 2007;68:392–417.
13. Mack SJ, Cano P, Hollenbach JA, He J, Hurley CK, Middleton D, et al. Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens. 2013;81:194–203.
14. Gragert L, Fingerson S, Albrecht M, Maers M, Kalaycio M, Hill BT. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood. 2014;124:2657–65.
15. Abdou AM, Gao X, Cozen W, Cerhan JR, Rothman N, Martin MP, et al. Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma. Leukemia. 2010;24:1055–8.